65,437 trials
Vocabulary Acquisition
Primary: Student Scientific Academic Vocabulary (SAV) Word Meaning (AVM) — 60.63; 62.43; 65.82; 67.35 percentage of vocabulary words correct — p=.022
Epilepsy, Temporal Lobe
Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks
Malignant Glioma
Primary: Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I Only — 200 mg
Dyslipidemias
Primary: Median % Change in Non-HDL-C From Baseline to Week 6 — -51.0; -40.8; -34.9 Median percent change from baseline — p=0.0008
Hoarding Disorder
Primary: Savings Inventory Revised (Frost, Steketee & Grisham, 2004; Tolin, Meunier, Frost & Steketee, 2011) — 62.41; 62.60; 53.41; 52.00 score on a scale
Osteoporosis, Postmenopausal
Primary: Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®. — 5.3; 5.18 Percent Change From Baseline in LS BMD
Acute Respiratory Failure
Primary: Number of Treatment-Emergent Severe Adverse Events [Safety] — 0; 0 number of safety events
Penile Cancer
Primary: Objective Response Rate (ORR) — 3; 15 Participants
Endodontic Disease · Post Operative Pain · Symptomatic Irreversible Pulpitis
Primary: Post-operative Pain Level 6 Hours on a Visual Analog Scale — 64.2; 43.1 units on a scale
Irritable Bowel Syndrome
Primary: Comparison of the Phase Angle Between IBS Patients and Healthy Individuals — 5.78; 6.35 degrees
Pancreatic Cancer · Metastatic Castration-resistant Prostate Cancer · Bladder Cancer
Primary: To Determine the Safety and Tolerability of NGM120 in Subjects — 1; 6; 6; 17 Participants
Advanced Solid Tumors
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 100; 100; 100; 100 percentage of participants
Status Epilepticus
Primary: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE — 79.59…
Ametropia · Astigmatism
Primary: Mean Distance Visual Acuity With Study Lenses at Day 30 — -0.07; -0.06 logMAR
Amyotrophic Lateral Sclerosis
Primary: Treatment-Emergent Adverse Events in More Than 2 Subjects Overall by System Organ Class and Preferred Term — 3; 3; 0; 2 Participants